Romania · Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.37 billion. The enterprise value is 1.68 billion.
| Market Cap | 1.37B |
| Enterprise Value | 1.68B |
Important Dates
The last earnings date was Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | Oct 1, 2026 |
Share Statistics
Antibiotice has 671.34 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Current Share Class | 671.34M |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.69% |
| Float | 227.94M |
Valuation Ratios
The trailing PE ratio is 43.33.
| PE Ratio | 43.33 |
| Forward PE | n/a |
| PS Ratio | 2.15 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 20.83 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 53.15 |
| EV / Sales | 2.64 |
| EV / EBITDA | 16.19 |
| EV / EBIT | 34.86 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.83, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.83 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 3.01 |
| Debt / FCF | -2.95 |
| Interest Coverage | 10.48 |
Financial Efficiency
Return on equity (ROE) is 3.39% and return on invested capital (ROIC) is 3.39%.
| Return on Equity (ROE) | 3.39% |
| Return on Assets (ROA) | 2.13% |
| Return on Invested Capital (ROIC) | 3.39% |
| Return on Capital Employed (ROCE) | 4.11% |
| Weighted Average Cost of Capital (WACC) | 4.80% |
| Revenue Per Employee | 471,572 |
| Profits Per Employee | 23,388 |
| Employee Count | 1,356 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.25 |
Taxes
In the past 12 months, Antibiotice has paid 5.68 million in taxes.
| Income Tax | 5.68M |
| Effective Tax Rate | 15.19% |
Stock Price Statistics
The stock price has decreased by -12.61% in the last 52 weeks. The beta is 0.25, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -12.61% |
| 50-Day Moving Average | 1.96 |
| 200-Day Moving Average | 2.25 |
| Relative Strength Index (RSI) | 54.04 |
| Average Volume (20 Days) | 159,401 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 638.98 million and earned 31.69 million in profits. Earnings per share was 0.05.
| Revenue | 638.98M |
| Gross Profit | 379.50M |
| Operating Income | 48.32M |
| Pretax Income | 37.37M |
| Net Income | 31.69M |
| EBITDA | 104.03M |
| EBIT | 48.32M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 2.04 million in cash and 313.54 million in debt, with a net cash position of -311.50 million or -0.46 per share.
| Cash & Cash Equivalents | 2.04M |
| Total Debt | 313.54M |
| Net Cash | -311.50M |
| Net Cash Per Share | -0.46 |
| Equity (Book Value) | 944.64M |
| Book Value Per Share | 1.41 |
| Working Capital | 264.05M |
Cash Flow
In the last 12 months, operating cash flow was 65.90 million and capital expenditures -172.16 million, giving a free cash flow of -106.26 million.
| Operating Cash Flow | 65.90M |
| Capital Expenditures | -172.16M |
| Depreciation & Amortization | 55.71M |
| Net Borrowing | 107.59M |
| Free Cash Flow | -106.26M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 59.39%, with operating and profit margins of 7.56% and 4.96%.
| Gross Margin | 59.39% |
| Operating Margin | 7.56% |
| Pretax Margin | 5.85% |
| Profit Margin | 4.96% |
| EBITDA Margin | 16.28% |
| EBIT Margin | 7.56% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 1.75%.
| Dividend Per Share | 0.04 |
| Dividend Yield | 1.75% |
| Dividend Growth (YoY) | -3.31% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 50.26% |
| Buyback Yield | 0.01% |
| Shareholder Yield | 1.77% |
| Earnings Yield | 2.31% |
| FCF Yield | -7.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 3.09 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.09 |
| Piotroski F-Score | 4 |